Healthcare / BiotechnologyNasdaqCM
$5.21
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-37.0M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$535M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-254.0%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-54.6M · FCF $-49.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | — | — | — | — | — | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — | — | — |
| Net Income | $-54.6M | $-54.6M | $-39.8M | $-29.8M | $-42.4M | $-33.2M | $-14.7M | $-16.4M | $-12.7M | $-10.6M | $-1.2M | $-828000.00 | $-26.2M | $-31.8M | $-21.1M | $-14.7M | $-12.6M | $-5.5M |
| EPS | -1.25 | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 | -5.42 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-49.5M | $-49.5M | — | $-24.5M | — | — | $-13.5M | $-15.3M | $-10.7M | — | $-248000.00 | — | — | $-36.2M | $-43.8M | $-20.3M | $-26.9M | $34.9M |
| Returns | ||||||||||||||||||
| ROE | -254.0% | -254.0% | -190.6% | 2059.0% | -510.1% | -118.2% | -39.5% | -90.8% | -80.3% | -67.0% | -202.3% | -45.0% | -77.0% | -85.6% | -31.9% | -47.5% | -28.5% | -23.9% |
| Growth & Yield | ||||||||||||||||||
| EPS Growth | -0.8% | -0.8% | 17.3% | 62.5% | 2.0% | 24.7% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.